The MarketReader Minute
💊 Incyte Falls Amid Missed EPS, While Regeneron Gains on Positive EYLEA HD Trial Results | Biotech Sector Insights
(IBB) declined over the past week, closing at $137.67. Comparatively, the SPDR S&P Biotech ETF (XBI) experienced a larger drop. Concerns regarding potential funding cuts from the National Institutes of Health (NIH) were also highlighted in these discussions.